Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials

Published:2018-09 Issue: Volume:62 Page:46-58
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Cui Lian,Chen Rongfen,Subedi Smriti,Yu Qian,Gong Yu,Chen Zeyu,Shi Yuling

Funder

National Science Foundation of China

National Science Foundation of Shanghai

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference40 articles.

1. Immunology of psoriasis;Michelle;Annu. Rev. Immunol.,2015

2. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data;Rustin;Br. J. Dermatol.,2012

3. The IL-23/Th17 axis in the immunopathogenesis of psoriasis;Di Cesare;J. Invest. Dermatol.,2009

4. Antibodies in the treatment of psoriasis: IL-12/23 p40 and IL-17a;Leonardi;Semin. Cutan. Med. Surg.,2016

5. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo;McGeachy;Nat. Immunol.,2009

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials;Joint Bone Spine;2024-05

2. Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study;Acta Dermato-Venereologica;2023-11-21

3. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies;RMD Open;2023-09

4. Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis;mAbs;2023-05-15

5. Living with Psoriasis Vulgaris and Multi-Treatment Failure: A Patient and Dermatologist Perspective;Dermatology and Therapy;2023-03-11